Literature DB >> 21770865

Catabolic factors and osteoarthritis-conditioned medium inhibit chondrogenesis of human mesenchymal stem cells.

Genoveva T H Heldens1, Esmeralda N Blaney Davidson, Elly L Vitters, B Willem Schreurs, Ester Piek, Wim B van den Berg, Peter M van der Kraan.   

Abstract

Articular cartilage has a very limited intrinsic repair capacity leading to progressive joint damage. Therapies involving tissue engineering depend on chondrogenic differentiation of progenitor cells. This chondrogenic differentiation will have to survive in a diseased joint. We postulate that catabolic factors in this environment inhibit chondrogenesis of progenitor cells. We investigated the effect of a catabolic environment on chondrogenesis in pellet cultures of human mesenchymal stem cells (hMSCs). We exposed chondrogenically differentiated hMSC pellets, to interleukin (IL)-1α, tumor necrosis factor (TNF)-α or conditioned medium derived from osteoarthritic synovium (CM-OAS). IL-1α and TNF-α in CM-OAS were blocked with IL-1Ra or Enbrel, respectively. Chondrogenesis was determined by chondrogenic markers collagen type II, aggrecan, and the hypertrophy marker collagen type X on mRNA. Proteoglycan deposition was analyzed by safranin o staining on histology. IL-1α and TNF-α dose-dependently inhibited chondrogenesis when added at onset or during progression of differentiation, IL-1α being more potent than TNF-α. CM-OAS inhibited chondrogenesis on mRNA and protein level but varied in extent between patients. Inhibition of IL-1α partially overcame the inhibitory effect of the CM-OAS on chondrogenesis whereas the TNF-α contribution was negligible. We show that hMSC chondrogenesis is blocked by either IL-1α or TNF-α alone, but that there are additional factors present in CM-OAS that contribute to inhibition of chondrogenesis, demonstrating that catabolic factors present in OA joints inhibit chondrogenesis, thereby impairing successful tissue engineering.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21770865     DOI: 10.1089/ten.TEA.2011.0083

Source DB:  PubMed          Journal:  Tissue Eng Part A        ISSN: 1937-3341            Impact factor:   3.845


  37 in total

1.  Anatomically shaped tissue-engineered cartilage with tunable and inducible anticytokine delivery for biological joint resurfacing.

Authors:  Franklin T Moutos; Katherine A Glass; Sarah A Compton; Alison K Ross; Charles A Gersbach; Farshid Guilak; Bradley T Estes
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-18       Impact factor: 11.205

Review 2.  Immune modulation to improve tissue engineering outcomes for cartilage repair in the osteoarthritic joint.

Authors:  Niamh Fahy; Eric Farrell; Thomas Ritter; Aideen E Ryan; J Mary Murphy
Journal:  Tissue Eng Part B Rev       Date:  2014-08-04       Impact factor: 6.389

3.  Tissue-engineered cartilage with inducible and tunable immunomodulatory properties.

Authors:  Katherine A Glass; Jarrett M Link; Jonathan M Brunger; Franklin T Moutos; Charles A Gersbach; Farshid Guilak
Journal:  Biomaterials       Date:  2014-04-22       Impact factor: 12.479

4.  Specific, Sensitive, and Stable Reporting of Human Mesenchymal Stromal Cell Chondrogenesis.

Authors:  Rodolfo E De la Vega; Maximiliano Scheu; Lennart A Brown; Christopher H Evans; Elisabeth Ferreira; Ryan M Porter
Journal:  Tissue Eng Part C Methods       Date:  2019-03       Impact factor: 3.056

Review 5.  Regenerative medicine in 2016: Important milestones on the way to clinical translation.

Authors:  Daniel A Grande
Journal:  Nat Rev Rheumatol       Date:  2017-01-05       Impact factor: 20.543

6.  The inhibition by interleukin 1 of MSC chondrogenesis and the development of biomechanical properties in biomimetic 3D woven PCL scaffolds.

Authors:  Paul H Ousema; Franklin T Moutos; Bradley T Estes; Arnold I Caplan; Donald P Lennon; Farshid Guilak; J Brice Weinberg
Journal:  Biomaterials       Date:  2012-09-19       Impact factor: 12.479

Review 7.  Stem cells in degenerative orthopaedic pathologies: effects of aging on therapeutic potential.

Authors:  Kivanc Atesok; Freddie H Fu; Ichiro Sekiya; Alexandra Stolzing; Mitsuo Ochi; Scott A Rodeo
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2015-08-23       Impact factor: 4.342

8.  * CRISPR-Based Epigenome Editing of Cytokine Receptors for the Promotion of Cell Survival and Tissue Deposition in Inflammatory Environments.

Authors:  Niloofar Farhang; Jonathan M Brunger; Joshua D Stover; Pratiksha I Thakore; Brandon Lawrence; Farshid Guilak; Charles A Gersbach; Lori A Setton; Robby D Bowles
Journal:  Tissue Eng Part A       Date:  2017-02-28       Impact factor: 3.845

9.  Inhibition of TAK1 and/or JAK can rescue impaired chondrogenic differentiation of human mesenchymal stem cells in osteoarthritis-like conditions.

Authors:  Henk M van Beuningen; Marloes L de Vries-van Melle; Elly L Vitters; Wim Schreurs; Wim B van den Berg; Gerjo J V M van Osch; Peter M van der Kraan
Journal:  Tissue Eng Part A       Date:  2014-03-25       Impact factor: 3.845

10.  Comparison of drug and cell-based delivery: engineered adult mesenchymal stem cells expressing soluble tumor necrosis factor receptor II prevent arthritis in mouse and rat animal models.

Authors:  Linda N Liu; Gang Wang; Kyle Hendricks; Keunmyoung Lee; Ernst Bohnlein; Uwe Junker; Joseph D Mosca
Journal:  Stem Cells Transl Med       Date:  2013-04-16       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.